-
Mashup Score: 0The Jack Birch Unit welcome Johns Hopkins Professor - 14 day(s) ago
The Jack Birch Unit were visited by Dr David McConkey, the Director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medical School.
Source: www.york.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19The Jack Birch Unit welcome Johns Hopkins Professor - 14 day(s) ago
The Jack Birch Unit were visited by Dr David McConkey, the Director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medical School.
Source: www.york.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Baltimore Region: Du e to the recent collapse of the Francis Scott Key Bridge, please anticipate delays when travelling to appointments. More information. WHERE: San Diego Convention Center, San Diego, CA HIGHLIGHTS: Personalized Vaccine Therapy for Liver Cancer “Neoantigen DNA Vaccine GNOS-PV02 and Pembrolizumab as Second-Line Treatment for Advanced Hepatocellular Carcinoma.” Abstract #1191 Mark Yarchoan, M.D., co-author and presenter. A Phase 1B/2A clinical trial led by Kimmel Cancer Center and its
Source: www.hopkinsmedicine.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Baltimore Region: Due to the recent collapse of the Francis Scott Key Bridge, please anticipate delays when travelling to appointments. More information. Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer, according to a clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute.
Source: www.hopkinsmedicine.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Iron Oxide Nanoparticles Inhibit Tumor Progression and Suppress Lung Metastases in Mouse Models of Breast Cancer - 27 day(s) ago
Systemic exposure to starch-coated iron oxide nanoparticles (IONPs) can stimulate antitumor T cell responses, even when little IONP is retained within the tumor. Here, we demonstrate in mouse models of metastatic breast cancer that IONPs can alter the host immune landscape, leading to systemic immune-mediated disease suppression. We report that a single intravenous injection of IONPs can inhibit primary tumor growth, suppress metastases, and extend survival. Gene expression analysis revealed the activation of Toll-like receptor (TLR) pathways involving signaling via Toll/Interleukin-1 receptor domain-containing adaptor-inducing IFN-β (TRIF), a TLR pathway adaptor protein. Requisite participation of TRIF in suppressing tumor progression was demonstrated with histopathologic evidence of upregulated IFN-regulatory factor 3 (IRF3), a downstream protein, and confirmed in a TRIF knockout syngeneic mouse model of metastatic breast cancer. Neither starch-coated polystyrene nanoparticles lackin
Source: pubs.acs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Johns Hopkins Proton Therapy Certificate Course - Johns Hopkins University - Continuing Education (CE) - 28 day(s) ago
Johns Hopkins University , Johns Hopkins Proton Therapy Certificate Course, 4/12/2024 8:00:00 AM – 4/13/2024 12:30:00 PM, The first Johns Hopkins Proton “Certificate” Course offered in the US. This certificate course is designed for radiation oncologists and medical physicists in-training, both domestic and international, as well as practicing radiation oncologists and medical physicists to obtain a broad understanding of the fundamentals of proton therapy, clinical evidence for proton therapy across disease sites, proton planning principles, and potential future directions of proton research and implementation. Participants in this course will gain an understanding of the clinical indications, drawbacks, treatment planning, biology, physics, and technology of proton therapy, which continue to evolve over time in the context of research advancements. This course is designed to teach radiation oncologists and medical physicists when to utilize and how to effectively deliver proton thera
Source: hopkinscme.cloud-cme.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Strategies for Advancing Sexual Orientation and Gender Identity Data Collection in Cancer Research - 1 month(s) ago
Although over 7% of American adults identify as lesbian, gay, bisexual, transgender, queer, intersex, or asexual (LGBTQIA+), 1 there is a dearth of cancer research in these populations. As such, there is broadening awareness of the need to collect sexual orientation and gender identity (SOGI) data as part of cancer research to produce appropriate evidence-based guidelines to inform clinical care and prevention efforts for LGBTQIA+ individuals in the future. The Sexual and Gender Minority (SGM) Interest
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Acute Myeloid Leukemia, Part II - Paul Christo MD - 1 month(s) ago
Leukemia is a medical term for cancer of the blood cells. Acute Myeloid Leukemia, known as AML is the most common acute leukemia in adults. AML is rapidly lethal if untreated, but overall survival has improved for those under age 65 from just 8 months in the late 1970s to 46 months in 2014. We’ll have […]
Source: paulchristomd.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Acute Myeloid Leukemia, Part I - Paul Christo MD - 1 month(s) ago
Leukemia is a medical term for cancer of the blood cells. Acute Myeloid Leukemia, known as AML is the most common acute leukemia in adults. AML is rapidly lethal if untreated, but overall survival has improved for those under age 65 from just 8 months in the late 1970s to 46 months in 2014. We’ll have […]
Source: paulchristomd.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Johns Hopkins Proton Therapy Certificate Course - Johns Hopkins University - Continuing Education (CE) - 1 month(s) ago
Johns Hopkins University , Johns Hopkins Proton Therapy Certificate Course, 4/12/2024 8:00:00 AM – 4/13/2024 12:30:00 PM, The first Johns Hopkins Proton “Certificate” Course offered in the US. This certificate course is designed for radiation oncologists and medical physicists in-training, both domestic and international, as well as practicing radiation oncologists and medical physicists to obtain a broad understanding of the fundamentals of proton therapy, clinical evidence for proton therapy across disease sites, proton planning principles, and potential future directions of proton research and implementation. Participants in this course will gain an understanding of the clinical indications, drawbacks, treatment planning, biology, physics, and technology of proton therapy, which continue to evolve over time in the context of research advancements. This course is designed to teach radiation oncologists and medical physicists when to utilize and how to effectively deliver proton thera
Source: hopkinscme.cloud-cme.comCategories: General Medicine News, Onc News and JournalsTweet
.@djmcconkey from @hopkinskimmel and @jhbladdercancer visited @YBRI_UoY last week, attending a workshop AI and machine learning and a lab meeting to discuss collaboration in #bladdercancer research! https://t.co/7WgpVW2N1w